Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Corvus Pharmaceuticals Inc (NASDAQ: CRVS) was $3.03 for the day, up 1.68% from the previous closing price of $2.98. In other words, the price has increased by $1.68 from its previous closing price. On the day, 0.67 million shares were traded.
Ratios:
Our analysis of CRVS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.54 and its Current Ratio is at 1.54. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on January 02, 2025, initiated with a Buy rating and assigned the stock a target price of $11.
On August 18, 2023, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $7.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on May 06 ’24 when Jones William Benton bought 20,000 shares for $1.73 per share. The transaction valued at 34,624 led to the insider holds 153,773 shares of the business.
MILLER RICHARD A MD bought 577,634 shares of CRVS for $1,000,000 on May 06 ’24. The President and CEO now owns 577,634 shares after completing the transaction at $1.73 per share.
Stock Price History:
Over the past 52 weeks, CRVS has reached a high of $10.00, while it has fallen to a 52-week low of $1.30. The 50-Day Moving Average of the stock is -26.55%, while the 200-Day Moving Average is calculated to be -40.80%.
Shares Statistics:
A total of 67.90M shares are outstanding, with a floating share count of 49.68M. Insiders hold about 27.09% of the company’s shares, while institutions hold 34.10% stake in the company.
